Loading...
Adjuvant weekly girentuximab following nephrectomy for high-risk renal cell carcinoma: the ARISER randomized clinical trial.
Chamie, K Donin, N Klöpfer, P Bevan, P Fall, B Wilhelm, O Störkel, S Said, J Gambla, M Hawkins, Robert E
Chamie, K
Donin, N
Klöpfer, P
Bevan, P
Fall, B
Wilhelm, O
Störkel, S
Said, J
Gambla, M
Hawkins, Robert E
Citations
Altmetric:
Abstract
Girentuximab is a chimeric monoclonal antibody that binds carbonic anhydrase IX, a cell surface glycoprotein ubiquitously expressed in clear cell renal cell carcinoma (ccRCC). Its safety and activity in phase 2 studies prompted investigation into its use as adjuvant monotherapy in participants with high-risk ccRCC.
Affiliation
Description
Date
2016-10-27
Publisher
Collections
Files
Loading...
From UNPAYWALL
Adobe PDF, 433.92 KB
Keywords
Type
Article
Citation
Adjuvant weekly girentuximab following nephrectomy for high-risk renal cell carcinoma: the ARISER randomized clinical trial. 2016 JAMA Oncol